Market News & Trends
Elite Pharmaceuticals & SunGen Pharma File ANDA
Elite Pharmaceuticals, Inc. recently announced it filed an Abbreviated New Drug Application (ANDA) with the US FDA for a generic version of an antibiotic product. This…
Sarepta Therapeutics Enters Strategic Relationship With Aldevron
Sarepta Therapeutics, Inc. and Aldevron recently announced they have entered into a long-term strategic relationship for the supply of plasmid DNA to fulfill Sarepta’s needs…
Acer Therapeutics Announces Exclusive License Agreement With Sanofi
Acer Therapeutics Inc. recently announced it has entered into an exclusive license agreement with Sanofi to acquire worldwide rights to osanetant, a clinical-stage, selective, non-peptide…
Merus Announces Strategic Collaboration With Betta Pharmaceuticals
Merus N.V. recently announced it has agreed to grant Betta Pharmaceuticals Co Ltd an exclusive license to develop and commercialize Merus Biclonics MCLA-129 in China. …
Allena Pharmaceuticals Achieves Alignment With FDA on Phase 3 Program
Allena Pharmaceuticals, Inc. recently announced it has reached alignment with the US FDA on both the design of URIROX-2, its second pivotal Phase 3 trial…
Outlook Therapeutics Closes Third Tranche of $20-Million Private Placement for Clinical Trials
Outlook Therapeutics, Inc. recently announced it closed on the third tranche (of four) of its $20-million private placement of common stock to BioLexis Pte. Limited,…
Histo-Scientific Research Laboratories & Vet Path Services Merge
Histo-Scientific Research Laboratories, Inc. (HSRL), has completed its merger with Vet Path Services (VPS) to create the leading provider of research and pre-clinical histology, pathology,…
Kiniksa Announces Rilonacept Interim Phase 2 Clinical Data; Initiates Pivotal Phase 3 Clinical Trial
Kiniksa Pharmaceuticals, Ltd.recently announced interim data from an open-label Phase 2 clinical trial of rilonacept, a weekly, subcutaneously-injected, recombinant fusion protein that blocks IL-1α and…
SunGen Pharma Receives Its Second & Third ANDA Approval from US FDA
SunGen Pharma recently announced it has received its second and third ANDA approval from the US FDA. The second ANDA is Amphetamine Salts, a generic…
Intensity Therapeutics Strengthens Intellectual Property Portfolio With Issuance of Several New Patents
Intensity Therapeutics, Inc. recently announced the receipt of patents protecting the company’s technology and its lead product candidate, INT230-6, in China, Japan, Korea, Russia, and…
EXCLUSIVE ONLINE CONTENT
Molex Expands European Manufacturing Footprint & Capabilities With State-of-the-Art Campus in Poland
Molex recently announced a major expansion of its global manufacturing footprint with the opening of a new campus in Katowice, Poland. The facility’s initial 23,000-square-meter manufacturing space will….
Kala Pharmaceuticals Completes Sale of EYSUVIS & INVELTYS to Alcon Inc
Kala Pharmaceuticals, Inc. recently announced it has completed the sale of its commercial portfolio and related intellectual property assets to Alcon Inc., a transaction that was….
Insightful Science Acquires Protein Metrics to Expand its R&D Solution to Include Proteomics
Insightful Science recently announced it has completed the transaction to acquire Protein Metrics, Inc. to expand the company’s R&D value chain to widen the biopharmaceutical protein analysis arena….
Acer Therapeutics & Relief Therapeutics Announce NDA Submission for ACER-001 for Treatment of Urea Cycle Disorders
Acer Therapeutics Inc. Relief Therapeutics recently announced the submission of a New Drug Application (NDA) to the US FDA for ACER-001 (sodium phenylbutyrate) for the treatment of Urea Cycle Disorders (UCDs)….